Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study
Muscle & Nerve · 2026-06 · 73 (6) · 1044-1057
DOI: 10.1002/mus.70211 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Muscle & Nerve, online erschienen am 15.03.2026. Verfasst von Sari Atula und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.
Abstract (Originalsprache)
Introduction/Aims Comorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden.
Methods
We included individuals with ≥ 2 MG diagnoses (ICD codes) in nationwide health registries between 2000 and 2020 and analyzed comorbidities before and after MG diagnosis and MG‐related treatments during follow‐up.
Results
Among 8819 people with MG (pwMG), 3159 were incident cases with data available ±5 years from diagnosis. Circulatory diseases were the most frequent comorbidity (19%–29%) before diagnosis, mostly explained by hypertension (13%–24%). After diagnosis, anemia and osteoporosis prevalence increased three to six fold. Mental health disorders were more frequent in younger (0–64 years) than older (≥ 65 years) pwMG. In the first year after diagnosis, acetylcholinesterase inhibitors (AChEIs) were the most used treatment in Finland (41%) and Sweden (34%), and corticosteroids (CSs) with nonsteroidal‐immunosuppressive therapy (NS‐IST) in Denmark (33%). By year 5, the proportion of pwMG receiving NS‐IST, CS, or their combination was similar in the three countries (Denmark 47%, Finland 40%, and Sweden 41%). Only 5%–7% remained treatment‐naive throughout follow‐up.
Discussion
MG treatment was broadly similar across the three Nordic countries, while also reflecting nation‐specific therapeutic guidelines. Many pwMG required multiple therapies, underscoring risks of long‐term immunosuppression and highlighting the need for vigilant management and future research of safer strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
- UCB, Stockholm, Sweden.
- UCB, Copenhagen, Denmark.
- UCB, Espoo, Finland.
ORCID-Profile: Sari Atula, Fredrik Piehl, Ingrid Schager, Fredrik Berggren, Karin Humle, Mari Savolainen, Didier Pitsi, Juha Mehtälä, Aino Vesikansa, Riina-Minna Väänänen, Tero Ylisaukko-Oja, John Vissing
Förderung
- UCB
Zitieren
APA
Atula, S., Piehl, F., Schager, I., Berggren, F., Humle, K., Savolainen, M., Pitsi, D., Mehtälä, J., Vesikansa, A., Väänänen, R. M., Ylisaukko-Oja, T., & Vissing, J. (2026). Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study. Muscle & Nerve, 73(6), 1044-1057. https://doi.org/10.1002/mus.70211
Vancouver
Atula S, Piehl F, Schager I, Berggren F, Humle K, Savolainen M, et al. Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study. Muscle & Nerve. 2026;73(6):1044-1057. doi:10.1002/mus.70211
BibTeX
@article{Atula2026,
author = {Atula, Sari and Piehl, Fredrik and Schager, Ingrid and Berggren, Fredrik and Humle, Karin and Savolainen, Mari and Pitsi, Didier and Mehtälä, Juha and Vesikansa, Aino and Väänänen, Riina-Minna and Ylisaukko-Oja, Tero and Vissing, John},
title = {Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study},
journal = {Muscle & Nerve},
year = {2026},
volume = {73},
number = {6},
pages = {1044--1057},
doi = {10.1002/mus.70211}
}
EUVIMED